Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SLC16A5 (ImmuneEditome ID:9121)

1. Gene summary of enriched editing regions for SLC16A5

Gene summary

Gene information	Gene symbol	SLC16A5
	Gene ID	9121
	GeneSynonyms	MCT5\|MCT6
	GeneCytomap	17q25.1
	GeneType	protein-coding
	GeneDescription	monocarboxylate transporter 6\|monocarboxylate transporter 5\|solute carrier family 16 (monocarboxylate transporter), member 5\|solute carrier family 16 (monocarboxylic acid transporters), member 5\|solute carrier family 16, member 5 (monocarboxylic acid transporter 6)
	GeneModificationdate	20230329
	UniprotID	O15375;J3KS19;J3QQW5;J3QL40;J3KT93
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr17:75098259-75099750:+	ENST00000582048.1	ENSG00000170190.14	SLC16A5	ncRNA_intronic	AluSx1,L2a	chr17:75098259-75099750:+.alignment
chr17:75098259-75099750:+	ENST00000585293.4	ENSG00000170190.14	SLC16A5	ncRNA_intronic	AluSx1,L2a	chr17:75098259-75099750:+.alignment
chr17:75101089-75104761:+	ENST00000329783.7	ENSG00000170190.14	SLC16A5	exonic	AluY,AluSp,MIR,AluSx4,AluSg4,L2a,MIRc,AluSg,AluSx3,AluJb	chr17:75101089-75104761:+.alignment
chr17:75101089-75104761:+	ENST00000450736.5	ENSG00000170190.14	SLC16A5	exonic	AluY,AluSp,MIR,AluSx4,AluSg4,L2a,MIRc,AluSg,AluSx3,AluJb	chr17:75101089-75104761:+.alignment
chr17:75101089-75104761:+	ENST00000538213.5	ENSG00000170190.14	SLC16A5	exonic	AluY,AluSp,MIR,AluSx4,AluSg4,L2a,MIRc,AluSg,AluSx3,AluJb	chr17:75101089-75104761:+.alignment
chr17:75101089-75104761:+	ENST00000578376.4	ENSG00000170190.14	SLC16A5	exonic	AluY,AluSp,MIR,AluSx4,AluSg4,L2a,MIRc,AluSg,AluSx3,AluJb	chr17:75101089-75104761:+.alignment
chr17:75101089-75104761:+	ENST00000580123.4	ENSG00000170190.14	SLC16A5	exonic	AluY,AluSp,MIR,AluSx4,AluSg4,L2a,MIRc,AluSg,AluSx3,AluJb	chr17:75101089-75104761:+.alignment

Top

2. Tumor-specific enriched editing regions for SLC16A5

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
ENSG00000170190.14,SLC16A5	KIRC	EAG	4.4175e-02
chr17:75101089-75104761:+	LUAD	EER	9.4373e-03
chr17:75098259-75099750:+	LUSC	EER	1.4289e-07
ENSG00000170190.14,SLC16A5	THCA	EAG	6.8213e-03

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr17:75098259-75099750:+	CESC	Cli	EER	4.9426e-02	9.3979e-03	-0.4329

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
ENSG00000170190.14,SLC16A5	HNSC	EAG	3.0670e-02	4.6212e-02	9.8140e+00

Top

3. Enriched editing regions and immune related genes for SLC16A5

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr17:75101089-75104761:+

ESCA

EER

ENSG00000120656,TAF12

0.3110

4.0558e-02

6.1656e-07

0.4400

DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPK;IGF2BP2;NOP56;NOP58;NUMA1;RBM10;SLTM;TARDBP

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr17:75101089-75104761:+

EER

ENSG00000244086,RPS20P35

0.3064

5.2054e-04

1.4034e-12

0.4530

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000233971,RPS20P10

0.2723

2.5813e-03

7.9074e-12

0.4390

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000223803,RPS20P14

0.2613

4.2272e-03

2.5665e-12

0.4482

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000228399,RP4-575N6.2

0.2484

7.2106e-03

3.3774e-11

0.4268

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000219274,RPS20P2

0.2458

8.2373e-03

2.9729e-12

0.4470

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000244245,RP11-120B7.1

0.2341

1.2908e-02

4.3651e-11

0.4246

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000243802,RP11-390K5.1

0.2072

3.2989e-02

2.7697e-10

0.4082

NK_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr17:75101089-75104761:+

ESCA

EER

ENSG00000120656,TAF12

0.3110

4.0558e-02

6.1656e-07

0.4400

DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPK;IGF2BP2;NOP56;NOP58;NUMA1;RBM10;SLTM;TARDBP

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr17:75101089-75104761:+

EER

ENSG00000244086,RPS20P35

0.3064

5.2054e-04

1.4034e-12

0.4530

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000233971,RPS20P10

0.2723

2.5813e-03

7.9074e-12

0.4390

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000223803,RPS20P14

0.2613

4.2272e-03

2.5665e-12

0.4482

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000228399,RP4-575N6.2

0.2484

7.2106e-03

3.3774e-11

0.4268

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000219274,RPS20P2

0.2458

8.2373e-03

2.9729e-12

0.4470

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000244245,RP11-120B7.1

0.2341

1.2908e-02

4.3651e-11

0.4246

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000243802,RP11-390K5.1

0.2072

3.2989e-02

2.7697e-10

0.4082

NK_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr17:75101089-75104761:+

ESCA

EER

ENSG00000120656,TAF12

0.3110

4.0558e-02

6.1656e-07

0.4400

DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPK;IGF2BP2;NOP56;NOP58;NUMA1;RBM10;SLTM;TARDBP

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr17:75101089-75104761:+

EER

ENSG00000244086,RPS20P35

0.3064

5.2054e-04

1.4034e-12

0.4530

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000233971,RPS20P10

0.2723

2.5813e-03

7.9074e-12

0.4390

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000223803,RPS20P14

0.2613

4.2272e-03

2.5665e-12

0.4482

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000228399,RP4-575N6.2

0.2484

7.2106e-03

3.3774e-11

0.4268

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000219274,RPS20P2

0.2458

8.2373e-03

2.9729e-12

0.4470

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000244245,RP11-120B7.1

0.2341

1.2908e-02

4.3651e-11

0.4246

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000243802,RP11-390K5.1

0.2072

3.2989e-02

2.7697e-10

0.4082

NK_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr17:75101089-75104761:+

ESCA

EER

ENSG00000120656,TAF12

0.3110

4.0558e-02

6.1656e-07

0.4400

DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPK;IGF2BP2;NOP56;NOP58;NUMA1;RBM10;SLTM;TARDBP

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr17:75101089-75104761:+

EER

ENSG00000244086,RPS20P35

0.3064

5.2054e-04

1.4034e-12

0.4530

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000233971,RPS20P10

0.2723

2.5813e-03

7.9074e-12

0.4390

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000223803,RPS20P14

0.2613

4.2272e-03

2.5665e-12

0.4482

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000228399,RP4-575N6.2

0.2484

7.2106e-03

3.3774e-11

0.4268

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000219274,RPS20P2

0.2458

8.2373e-03

2.9729e-12

0.4470

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000244245,RP11-120B7.1

0.2341

1.2908e-02

4.3651e-11

0.4246

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000243802,RP11-390K5.1

0.2072

3.2989e-02

2.7697e-10

0.4082

NK_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr17:75101089-75104761:+

ESCA

EER

ENSG00000120656,TAF12

0.3110

4.0558e-02

6.1656e-07

0.4400

DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPK;IGF2BP2;NOP56;NOP58;NUMA1;RBM10;SLTM;TARDBP

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr17:75101089-75104761:+

EER

ENSG00000244086,RPS20P35

0.3064

5.2054e-04

1.4034e-12

0.4530

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000233971,RPS20P10

0.2723

2.5813e-03

7.9074e-12

0.4390

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000223803,RPS20P14

0.2613

4.2272e-03

2.5665e-12

0.4482

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000228399,RP4-575N6.2

0.2484

7.2106e-03

3.3774e-11

0.4268

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000219274,RPS20P2

0.2458

8.2373e-03

2.9729e-12

0.4470

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000244245,RP11-120B7.1

0.2341

1.2908e-02

4.3651e-11

0.4246

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:75101089-75104761:+

EER

ENSG00000243802,RP11-390K5.1

0.2072

3.2989e-02

2.7697e-10

0.4082

NK_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

More results

Top

4. Enriched editing regions and immune related splicing for SLC16A5

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000170190.14,SLC16A5

ESCA

EAG

ENSG00000183856.6

chr1

156561837:156562001:156562586:156562665

0.3941

2.1244e-02

5.3243e-06

0.4005

ADAR;AUH;BCCIP;BUD13;CSTF2T;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184

GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

chr17:75101089-75104761:+

ESCA

EER

ENSG00000130489.8

chr22

50523567:50524424:50525471:50525606

0.3914

2.3691e-02

3.3463e-06

0.4130

DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPK;IGF2BP2;NOP56;NOP58;RBM10;SLTM

T_cells_CD4_memory_activated

GSVA_HALLMARK_PEROXISOME

chr17:75101089-75104761:+

ESCA

EER

ENSG00000064270.8

chr16

84461713:84461812:84461987:84462129

0.3647

2.8093e-02

1.8896e-06

0.4438

DKC1;EIF4A3;ELAVL1;FBL;FUS;IGF2BP2;NOP56;NOP58;TARDBP

Macrophages_M1

GSVA_HALLMARK_PANCREAS_BETA_CELLS

ENSG00000170190.14,SLC16A5

ESCA

EAG

ENSG00000187961.9

chr1

962354:963504:963919:964008

0.3600

4.7345e-02

7.6998e-06

0.4053

ADAR;AUH;BCCIP;BUD13;CSTF2T;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;LSM11;MOV10;NONO;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

ENSG00000170190.14,SLC16A5

ESCA

EAG

ENSG00000105325.9

chr19

3534420:3534522:3534794:3534836

0.4760

1.1212e-03

4.8653e-07

0.4386

ADAR;AUH;BCCIP;BUD13;CSTF2T;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184

T_cells_CD4_memory_activated

GSVA_HALLMARK_HEME_METABOLISM

ENSG00000170190.14,SLC16A5

ESCA

EAG

ENSG00000180488.10

chr1

77860004:77860126:77861223:77861322

0.3772

1.8006e-02

6.8720e-06

0.4159

ADAR;AUH;BCCIP;BUD13;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184

T_cells_CD4_memory_activated

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

ENSG00000170190.14,SLC16A5

ESCA

EAG

ENSG00000115459.13

chr2

85355075:85355598:85356966:85357025

0.3179

4.8685e-02

4.8688e-05

0.4022

ADAR;BCCIP;BUD13;CSTF2T;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;LSM11;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184

ELMOD3

T_cells_CD4_memory_resting

GSVA_HALLMARK_GLYCOLYSIS

ENSG00000170190.14,SLC16A5

ESCA

EAG

ENSG00000076604.10

chr17

28747569:28747754:28747842:28747947

0.5230

1.4419e-04

3.0032e-08

0.4760

AUH;BCCIP;BUD13;CSTF2T;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184

TRAF4

Mast_cells_activated

GSVA_HALLMARK_GLYCOLYSIS

ENSG00000170190.14,SLC16A5

ESCA

EAG

ENSG00000168591.11

chr17

44187233:44187431:44187675:44188009:44189021:44189079

0.3506

1.4716e-02

7.6419e-06

0.4194

ADAR;AUH;BCCIP;BUD13;CSTF2T;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184

GSVA_HALLMARK_ALLOGRAFT_REJECTION

ENSG00000170190.14,SLC16A5

ESCA

EAG

ENSG00000010327.6

chr3

52516691:52516768:52516983:52517109

0.3909

6.8315e-03

2.1428e-06

0.4417

DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPL;IGF2BP1;LSM11;NOP56;NOP58;PRPF8;SF3B4;SLTM;SRSF3;TAF15

STAB1

T_cells_CD4_memory_activated

GSVA_HALLMARK_BILE_ACID_METABOLISM

More results

Top

5. Enriched editing regions and immune infiltration for SLC16A5

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr17:75098259-75099750:+	BLCA	EER	T_cells_regulatory_(Tregs)	1.0453e-02	-0.2320
chr17:75101089-75104761:+	BLCA	EER	NK_cells_activated	1.2292e-02	-0.2721
ENSG00000170190.14,SLC16A5	BLCA	EAG	Dendritic_cells_activated	4.4122e-02	0.1519
chr17:75101089-75104761:+	BRCA	EER	T_cells_regulatory_(Tregs)	3.3572e-03	0.1389
ENSG00000170190.14,SLC16A5	BRCA	EAG	Mast_cells_activated	7.4858e-03	0.1222
chr17:75098259-75099750:+	COAD	EER	NK_cells_activated	5.3360e-03	0.3525
chr17:75098259-75099750:+	ESCA	EER	T_cells_CD4_memory_activated	4.3861e-03	0.2993
chr17:75101089-75104761:+	ESCA	EER	T_cells_CD4_memory_activated	8.0151e-03	0.2430
ENSG00000170190.14,SLC16A5	ESCA	EAG	Mast_cells_activated	8.8555e-03	-0.2361
ENSG00000170190.14,SLC16A5	HNSC	EAG	Plasma_cells	3.3123e-02	0.1713
chr17:75098259-75099750:+	KIRC	EER	Eosinophils	4.4159e-05	0.7578
ENSG00000170190.14,SLC16A5	KIRC	EAG	NK_cells_activated	7.0724e-03	0.2971
chr17:75098259-75099750:+	KIRP	EER	T_cells_CD4_naive	1.1024e-05	0.7808
ENSG00000170190.14,SLC16A5	KIRP	EAG	T_cells_CD4_naive	3.2350e-06	0.5860
ENSG00000170190.14,SLC16A5	LAML	EAG	T_cells_regulatory_(Tregs)	3.3985e-02	-0.2575
chr17:75098259-75099750:+	LUAD	EER	Neutrophils	2.3454e-02	-0.1764
chr17:75101089-75104761:+	LUAD	EER	Mast_cells_resting	3.7064e-02	0.1518
ENSG00000170190.14,SLC16A5	LUAD	EAG	Neutrophils	2.7137e-03	-0.1798
chr17:75101089-75104761:+	LUSC	EER	Plasma_cells	4.2583e-02	0.1775
ENSG00000170190.14,SLC16A5	LUSC	EAG	B_cells_naive	3.4896e-04	0.2666
ENSG00000170190.14,SLC16A5	MESO	EAG	Mast_cells_activated	6.1623e-05	0.5900
chr17:75098259-75099750:+	OV	EER	Macrophages_M2	6.6073e-03	-0.2362
chr17:75098259-75099750:+	PAAD	EER	B_cells_naive	9.9032e-04	0.4518
chr17:75101089-75104761:+	PAAD	EER	Plasma_cells	8.3456e-03	0.3462
ENSG00000170190.14,SLC16A5	PRAD	EAG	Dendritic_cells_activated	5.2977e-05	0.4286
chr17:75098259-75099750:+	READ	EER	T_cells_CD4_memory_activated	1.0016e-02	-0.5613
ENSG00000170190.14,SLC16A5	READ	EAG	T_cells_follicular_helper	4.9933e-03	0.4578
ENSG00000170190.14,SLC16A5	SKCM	EAG	NK_cells_resting	1.9929e-02	0.2302
chr17:75101089-75104761:+	STAD	EER	Dendritic_cells_resting	2.5227e-02	0.1362
ENSG00000170190.14,SLC16A5	TGCT	EAG	Mast_cells_activated	1.0272e-02	0.4115
chr17:75098259-75099750:+	THCA	EER	Mast_cells_resting	1.8824e-02	0.4856
ENSG00000170190.14,SLC16A5	THCA	EAG	Neutrophils	3.1582e-02	-0.1506
ENSG00000170190.14,SLC16A5	THYM	EAG	B_cells_naive	1.8990e-02	-0.4258
chr17:75101089-75104761:+	UCEC	EER	Mast_cells_activated	7.6185e-03	0.4318
ENSG00000170190.14,SLC16A5	UCEC	EAG	Macrophages_M0	3.6824e-02	-0.3194
ENSG00000170190.14,SLC16A5	UVM	EAG	Plasma_cells	1.2254e-04	0.7159

Top

6. Enriched editing regions and immune gene sets for SLC16A5

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000170190.14,SLC16A5	LUAD	EAG	3.9694e-03	-0.1729	3.9610e-02	-0.1240	1.8914e-02	-0.1412	3.2231e-07	-0.3017
chr17:75101089-75104761:+	STAD	EER	1.0243e-02	-0.1560	4.4060e-02	-0.1227	4.8345e-03	-0.1710	1.0157e-02	-0.1562

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr17:75101089-75104761:+	BLCA	GSVA_HALLMARK_SPERMATOGENESIS	EER	1.1784e-03	-0.3480
ENSG00000170190.14,SLC16A5	BLCA	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EAG	2.5415e-04	-0.2724
chr17:75098259-75099750:+	BLCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	3.2601e-05	0.3682
chr17:75101089-75104761:+	BRCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.1680e-05	0.2064
chr17:75098259-75099750:+	BRCA	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	2.7655e-03	0.3022
ENSG00000170190.14,SLC16A5	BRCA	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	7.4217e-03	-0.1223
ENSG00000170190.14,SLC16A5	CESC	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	1.5965e-03	-0.3087
chr17:75098259-75099750:+	COAD	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	3.2393e-02	-0.2743
ENSG00000170190.14,SLC16A5	COAD	GSVA_HALLMARK_APOPTOSIS	EAG	6.4054e-04	-0.3085
chr17:75098259-75099750:+	ESCA	GSVA_HALLMARK_HYPOXIA	EER	6.3091e-04	0.3554
chr17:75101089-75104761:+	ESCA	GSVA_HALLMARK_PEROXISOME	EER	3.3167e-04	-0.3249
ENSG00000170190.14,SLC16A5	ESCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	1.0737e-02	-0.2302
ENSG00000170190.14,SLC16A5	HNSC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	4.2204e-04	-0.2798
ENSG00000170190.14,SLC16A5	KICH	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	7.3566e-03	-0.5435
ENSG00000170190.14,SLC16A5	KIRC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	8.8788e-04	-0.3623
chr17:75098259-75099750:+	KIRP	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.4294e-02	-0.4681
ENSG00000170190.14,SLC16A5	KIRP	GSVA_HALLMARK_HEME_METABOLISM	EAG	1.8146e-03	-0.4149
ENSG00000170190.14,SLC16A5	LAML	GSVA_HALLMARK_DNA_REPAIR	EAG	3.9168e-02	-0.2507
chr17:75098259-75099750:+	LUAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	4.9220e-02	0.1534
ENSG00000170190.14,SLC16A5	LUAD	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.0786e-12	-0.4113
chr17:75101089-75104761:+	LUAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	4.3151e-03	-0.2067
ENSG00000170190.14,SLC16A5	LUSC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.2400e-11	-0.4768
chr17:75101089-75104761:+	LUSC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.1973e-04	-0.3175
ENSG00000170190.14,SLC16A5	MESO	GSVA_HALLMARK_DNA_REPAIR	EAG	2.0312e-02	-0.3657
ENSG00000170190.14,SLC16A5	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.2369e-03	-0.2090
chr17:75098259-75099750:+	OV	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	2.6902e-02	0.1934
chr17:75101089-75104761:+	OV	GSVA_HALLMARK_PROTEIN_SECRETION	EER	3.4527e-04	-0.2386
chr17:75101089-75104761:+	PAAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.6554e-02	-0.3162
ENSG00000170190.14,SLC16A5	PAAD	GSVA_HALLMARK_ANGIOGENESIS	EAG	2.2352e-04	-0.3901
chr17:75098259-75099750:+	PAAD	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	2.9066e-02	0.3089
ENSG00000170190.14,SLC16A5	PRAD	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	3.4011e-03	-0.3179
chr17:75098259-75099750:+	READ	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	8.6741e-03	-0.5701
ENSG00000170190.14,SLC16A5	READ	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.6802e-02	-0.3960
ENSG00000170190.14,SLC16A5	SARC	GSVA_HALLMARK_HYPOXIA	EAG	2.7473e-03	0.5731
ENSG00000170190.14,SLC16A5	SKCM	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	2.7575e-04	-0.3528
chr17:75101089-75104761:+	STAD	GSVA_HALLMARK_PROTEIN_SECRETION	EER	9.4642e-07	-0.2931
ENSG00000170190.14,SLC16A5	STAD	GSVA_HALLMARK_P53_PATHWAY	EAG	7.9394e-08	-0.3114
chr17:75098259-75099750:+	STAD	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	7.3810e-03	-0.2165
chr17:75098259-75099750:+	THCA	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.1945e-02	0.5148
ENSG00000170190.14,SLC16A5	THCA	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.1981e-03	-0.2253
ENSG00000170190.14,SLC16A5	THYM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	9.6313e-04	-0.5718
chr17:75101089-75104761:+	UCEC	GSVA_HALLMARK_SPERMATOGENESIS	EER	3.4492e-03	-0.4685
ENSG00000170190.14,SLC16A5	UVM	GSVA_HALLMARK_DNA_REPAIR	EAG	4.3945e-02	-0.4237

Top

7. Enriched editing regions and drugs for SLC16A5

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr17:75101089-75104761:+	BLCA	Epothilone.B	EER	2.6153e-02	0.2426
ENSG00000170190.14,SLC16A5	BLCA	CMK	EAG	1.0968e-05	0.3247
chr17:75098259-75099750:+	BLCA	CCT007093	EER	1.2225e-03	0.2906
chr17:75098259-75099750:+	BRCA	KIN001.135	EER	4.4451e-02	-0.2056
chr17:75101089-75104761:+	BRCA	A.770041	EER	6.5404e-04	-0.1613
ENSG00000170190.14,SLC16A5	CESC	Docetaxel	EAG	2.6525e-02	0.2197
chr17:75098259-75099750:+	CESC	Lapatinib	EER	6.9474e-03	-0.4481
chr17:75098259-75099750:+	COAD	Bicalutamide	EER	2.2842e-03	-0.3835
ENSG00000170190.14,SLC16A5	COAD	Cyclopamine	EAG	1.6912e-03	0.2872
chr17:75098259-75099750:+	ESCA	CGP.60474	EER	1.2600e-04	-0.3953
ENSG00000170190.14,SLC16A5	ESCA	BMS.708163	EAG	2.9488e-02	0.1972
chr17:75101089-75104761:+	ESCA	CMK	EER	1.7493e-05	-0.3842
ENSG00000170190.14,SLC16A5	HNSC	DMOG	EAG	2.6809e-03	0.2396
ENSG00000170190.14,SLC16A5	KICH	FH535	EAG	2.4674e-03	0.6001
chr17:75098259-75099750:+	KIRC	Epothilone.B	EER	2.2977e-03	0.6154
ENSG00000170190.14,SLC16A5	KIRC	Bexarotene	EAG	3.3925e-04	0.3884
ENSG00000170190.14,SLC16A5	KIRP	Bexarotene	EAG	1.2495e-03	0.4279
chr17:75098259-75099750:+	KIRP	Epothilone.B	EER	3.3970e-03	0.5846
ENSG00000170190.14,SLC16A5	LAML	Cyclopamine	EAG	1.0087e-02	0.3100
chr17:75098259-75099750:+	LAML	JNK.Inhibitor.VIII	EER	2.1452e-02	0.3540
ENSG00000170190.14,SLC16A5	LUAD	BMS.708163	EAG	8.7105e-04	0.1993
chr17:75101089-75104761:+	LUAD	ABT.263	EER	3.7173e-02	-0.1521
ENSG00000170190.14,SLC16A5	LUSC	CGP.082996	EAG	7.0028e-04	0.2531
chr17:75098259-75099750:+	LUSC	AZD7762	EER	2.3761e-02	-0.2542
chr17:75101089-75104761:+	LUSC	Bicalutamide	EER	4.3722e-03	0.2475
ENSG00000170190.14,SLC16A5	MESO	Doxorubicin	EAG	2.0892e-05	0.6187
chr17:75101089-75104761:+	OV	AS601245	EER	3.3319e-04	0.2392
ENSG00000170190.14,SLC16A5	OV	ABT.888	EAG	1.9048e-03	-0.2011
chr17:75098259-75099750:+	OV	DMOG	EER	3.1741e-02	0.1878
chr17:75101089-75104761:+	PAAD	Gefitinib	EER	2.9522e-02	0.2885
ENSG00000170190.14,SLC16A5	PAAD	Docetaxel	EAG	1.4197e-03	0.3446
ENSG00000170190.14,SLC16A5	PRAD	IPA.3	EAG	2.1738e-02	-0.2517
chr17:75098259-75099750:+	READ	AZD.2281	EER	3.0389e-03	0.6278
ENSG00000170190.14,SLC16A5	READ	CMK	EAG	1.8014e-02	-0.3921
ENSG00000170190.14,SLC16A5	SARC	CGP.60474	EAG	1.2403e-04	-0.6928
ENSG00000170190.14,SLC16A5	SKCM	CGP.082996	EAG	1.6871e-02	0.2362
ENSG00000170190.14,SLC16A5	STAD	AZ628	EAG	2.2411e-05	0.2483
chr17:75101089-75104761:+	STAD	AMG.706	EER	2.0651e-04	-0.2244
chr17:75098259-75099750:+	STAD	CHIR.99021	EER	3.5034e-02	0.1711
chr17:75098259-75099750:+	THCA	AICAR	EER	8.0735e-03	0.5382
ENSG00000170190.14,SLC16A5	THCA	Bexarotene	EAG	5.6211e-04	0.2394
ENSG00000170190.14,SLC16A5	THYM	Erlotinib	EAG	1.9986e-02	-0.4226
chr17:75101089-75104761:+	UCEC	ABT.263	EER	2.5297e-04	0.5670
ENSG00000170190.14,SLC16A5	UVM	Metformin	EAG	3.1779e-05	0.7546

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER	ENST	UniprotID	DrugBankID	Drug	DrugType
chr17:75101089-75104761:+	ENST00000329783.7	O15375	DB00119	Pyruvic acid	SmallMoleculeDrug
chr17:75101089-75104761:+	ENST00000450736.5	O15375	DB00119	Pyruvic acid	SmallMoleculeDrug
chr17:75101089-75104761:+	ENST00000538213.5	O15375	DB00119	Pyruvic acid	SmallMoleculeDrug
chr17:75101089-75104761:+	ENST00000580123.4	O15375	DB00119	Pyruvic acid	SmallMoleculeDrug